American Society of Hirudotherapy

Lipodermatosclerosis

Investigational use for chronic lipodermatosclerosis; no study in this condition was identified, only small series in venous ulcer and varicose disease.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for lipodermatosclerosis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
What evidence exists?
Tier C (investigational). No study of leech therapy specific to lipodermatosclerosis was identified; the nearest evidence is small series and case reports in varicose veins and venous ulcers and an open randomized trial in varicose veins, and none of the randomized trials found studied lipodermatosclerosis itself.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over the gaiter area for 5 to 10 days
  • Local skin infection or, rarely, Aeromonas infection (especially concerning in chronically inflamed skin)
  • Triggering an active venous ulcer in already fragile skin
  • Allergic reaction to leech saliva (uncommon)
  • Cellulitis or erysipelas of the affected leg
  • Worsening anemia from cumulative blood loss
  • Delay or replacement of evidence-based compression and venous reflux management
Who should not consider this
  • Patients with an active venous ulcer with cellulitis or significant infection
  • Patients with critical limb ischemia (ABI under 0.4 — leech application risks tissue breakdown)
  • Patients not engaged with graduated compression therapy
  • Patients with untreated significant superficial or deep venous reflux without specialty evaluation
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Patients with poorly controlled diabetes (higher infection risk)
What to ask your clinician
  • Has my venous insufficiency been evaluated by duplex ultrasound for superficial / deep reflux and obstruction?
  • Am I a candidate for endothermal venous ablation, sclerotherapy, or surgical management of varicose veins?
  • Am I in a properly fitted graduated compression stocking (20 to 30 mmHg or higher)?
  • Have I tried weight management, exercise, and leg elevation?
  • If I have an active venous ulcer, what is the wound-care plan?
  • Where exactly will leeches be placed — over fibrotic skin, NEVER on an active ulcer base?
  • What is the practitioner's experience and Aeromonas-prevention plan?
When to seek urgent care
  • Sudden severe leg pain, swelling, redness, or warmth (cellulitis, erysipelas, or DVT — needs antibiotics or anticoagulation)
  • New or rapidly enlarging leg ulcer with discharge or odor
  • Sudden severe leg pain with coldness, pallor, or pulselessness (acute limb ischemia — call 911)
  • Spreading red streaks up the leg (lymphangitis)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for lipodermatosclerosis.
  • Small uncontrolled series in venous ulcers and varicose veins do NOT establish efficacy on fibrotic skin changes, long-term disease progression or ulcer prevention.
  • Mechanism rationale (fibrinolysis, anti-inflammation) does NOT replace compression or treatment of underlying venous reflux.
  • Leech therapy is not a substitute for evidence-based graduated compression and venous reflux management.
  • Active venous ulcers and cellulitis require wound care and antibiotics, NOT complementary therapy.

Clinical Profile

Category
Dermatological
ICD-10
I87.2
Safety tier
Medium

Evidence Summary

Lipodermatosclerosis represents end-stage chronic venous insufficiency with fibrotic remodeling of the gaiter area. No study of leech therapy specifically for lipodermatosclerosis was identified in PubMed, Europe PMC, ClinicalTrials.gov or the Baskova and Isakhanyan (2004) monograph; use is investigational and the rationale is mechanistic only. Indirect evidence exists only in neighbouring venous disease: an open randomized trial in varicose veins (Nigar and Alam 2011, n=50, leeches vs compression stockings; pigmentation improved in the leech group), a prospective series of 20 patients with complicated varicose veins and ulcers (Bapat et al. 1998; all ulcers healed, hyperpigmentation decreased in 75%), and older series in post-thrombotic syndrome (Eldor et al., 87 patients) and trophic ulcers (Shchekotov, 67 patients) summarized by Baskova and Isakhanyan (2004); a 2025 Azerbaijani series (Farzali et al.) reported only 33% success in 30 patients with varicose veins. None of these reports induration or fibrosis as an outcome. The proposed rationale combines fibrinolytic action of salivary enzymes with reduction of chronic local inflammation, but any effect on plaque softening or disease progression is unproven. Standard care (compression, treatment of venous reflux, weight management) should be optimized first, and leech therapy has no established role beyond exploratory use.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan do not mention lipodermatosclerosis by name; the closest is their description of postphlebitic syndrome: swelling, hardening and darkening of the skin (hyperpigmentation) around the ankle and in the lower third of the leg, and an ulcer[B1].
  • They retell the observation of Eldor, Orevi and Rigbi (1998) in 87 patients with postphlebitic syndrome: as described, after leeches blood circulation in the skin improved, the skin color changed from purplish red to pale pink, and chronic skin ulcers healed in 15 patients; no comparison group is mentioned in the retelling[B1].
  • In a series of 20 patients with varicose ulcers (Bapat and colleagues, 1998), leeches were placed on the skin around the ulcers and, as described, hyperpigmentation decreased in most patients; the authors of the book themselves conclude that the question requires further verification[B1].
  • Michalsen et al. do not use the word “lipodermatosclerosis” either; the closest in their book is Storck’s paragraph in the chapter on rheumatic diseases about indurations (hardenings), which can occur in superficial veins as well as in the surrounding tissues[B3].
  • Storck writes in the chapter on rheumatic diseases that leeches are an effective method in phlebitis and residual indurations next to the inflammation, and that the area of induration, as described, should become markedly softer and the dark bluish discoloration paler; this paragraph has no numbers of patients or follow-up period[B3].
  • Flecken and Michalsen write: in local disorders of wound healing (for example, leg ulcers), leeches must not be placed directly on the affected spot, since this may create new foci of ulcers; Michalsen et al. add that leeches are never placed directly on skin with marked dermatitis or ulceration[B3].
  • In their list of contraindications, Baskova and Isakhanyan name, among other things, hemophilia, hemorrhagic diatheses, anemias and the simultaneous prescription of anticoagulants, that is, medicines that thin the blood (especially long-term and daily use); Flecken and Michalsen call any hemophilia and the simultaneous use of anticoagulants (Marcumar, warfarin, heparin and heparinoids are named) an absolute contraindication, and in anemia, in their words, treatment involving blood loss is generally contraindicated[B1][B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active deep vein thrombosis (acute phase)
  • Critical limb ischemia (ABI <0.4)
  • Active venous ulcer with cellulitis

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.